

## Anti-PDCD1/PD-1/CD279 Antibody (Camrelizumab)

### Introduction

Camrelizumab (SHR-1210) is a humanized IgG4-κ antibody. PD-1 Camrelizumab binds to leukemia cells with a high affinity of 3 nM. PD-1 Bind, inhibit PD-1 and PD-L1. The combined effect. IC50 Camrelizumab is a potent anti-PD-1/PD-L1 Active molecules that can be used in cancer research, including non-small cell lung cancer, esophageal squamous cell carcinoma, Hodgkin's lymphoma and advanced liver cancer.

### Product parameters

Alternative Names	HR-301210, SHR 1210, INCSHR-1210
Target Accession	Q15116
Target	PDCD1 / PD-1 / CD279
CAS number	1798286-48-2
Molecular Weight	145.76 kDa
Host	CHO
Reactivity	Human, Cynomolgus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4SP
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human PD-1 His at 2 ug/mL can bind Anti-PDCD1/PD-1/CD279 Antibody (Camrelizumab), EC50=0.008247 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## ■ Note

1. This product is for scientific research use only.



**APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

